Inhibiting TGF-β with small molecules and antibodies shows impressive potency in treating many diseases including lung diseases ranging from acute respiratory distress syndrome (ARDS) to chronic fibrosis [21–25] and quite recently COVID-19 [26–28]. The gene discussed is TGFB1; the disease is acute respiratory distress syndrome.